Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Financings

Lixte Biotechnology Holdings, Inc.

Financings

RaiseDate
Registered direct offering of common Units (or Pre-Funded Units) of common stock and common warrants
Announced: about US$4.3M · US$4.09 a unit · Warrants at US$3.96 for 60 months · Spartan Capital Securities, LLC
Dealers: Spartan Capital Securities, LLC (lead)
Use of proceeds: General corporate purposes and working capital
Dec 18, 2025
Registered direct offering of shares of Common Stock (or Pre-Funded Warrants)
Closed: US$1.5M raised · US$1.54 a share · Spartan Capital Securities, LLC
Dealers: Spartan Capital Securities, LLC (lead)
Use of proceeds: General corporate purposes and working capital
Jul 8, 2025
Private placement of common stock (or pre-funded warrants), Series B convertible preferred stock and common warrants
Closed: US$5M raised · Warrants at US$1 for 60 months · Spartan Capital Securities, LLC
Dealers: Spartan Capital Securities, LLC (lead)
Use of proceeds: General corporate purposes and working capital
Jul 2, 2025
Registered direct offering of registered direct offering
Closed: US$1.05M raised · US$2.415 a share · Warrants at US$2.29 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and other general corporate purposes
Mar 27, 2025
Public offering of securities under Form S-1 registration statement
Cancelled: public offering
Feb 10, 2025

Read by 6ix AI from the company's releases